PULM | tickerfilter.com

Fundamental analysis

17%

Profitability 8%

Dept financing 35%

Liquidity 50%

Performance 14%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.36%

1 Month

-4.41%

3 Months

21.15%

6 Months

281.87%

1 Year

287.03%

2 Year

127.30%

Key data

Stock price

$7.16

P/E Ratio

0.00

DAY RANGE

$7.14 - $7.68

EPS

-$2.96

52 WEEK RANGE

$1.55 - $10.40

52 WEEK CHANGE

$302.25

MARKET CAP

7.816 M

YIELD

N/A

SHARES OUTSTANDING

3.652 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

-3.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$26,674

AVERAGE 30 VOLUME

$40,725

Company detail

CEO: Teofilo Raad
Region: US
Website: pulmatrix.com
Employees: 20
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pulmatrix, Inc. discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology. Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis, and in patients with cystic fibrosis, is in Phase 1b clinical trials.

PULM - Pulmatrix, Inc.